Get the Stockscreener App
3.57
1.13%
0.04
After Hours:
3.59
0.02
+0.56%
Briacell Therapeutics Corp stock is traded at $3.57, with a volume of 108.24K.
It is up +1.13% in the last 24 hours and up +5.93% over the past month.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
See More
Previous Close:
$3.53
Open:
$3.48
24h Volume:
108.24K
Relative Volume:
0.38
Market Cap:
$31.06M
Revenue:
-
Net Income/Loss:
$-30.98M
P/E Ratio:
-0.2923
EPS:
-12.2116
Net Cash Flow:
$-31.84M
1W Performance:
-4.29%
1M Performance:
+5.93%
6M Performance:
-12.29%
1Y Performance:
-53.73%
1-Day Range:
$3.46
$3.60
1-Week Range:
$3.46
$3.80
52-Week Range:
$2.60
$14.68
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
3.57 | 34.19M | 0 | -30.98M | -31.84M | -12.21 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
(BCT) Strategic Equity Report (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics Corp (BCTXW) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Briacell Therapeutics Corp (BCTX) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Enterprise value to revenue forward of BriaCell Therapeutics Corp. – NASDAQ:BCTXZ - TradingView
Briacell Therapeutics Corp (BCTX) Peer Comparison – Compare with Others - valueresearchonline.com
Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. - marketscreener.com
BriaCell's Cell-Based ‘Melanoma’ Enters the Skin Cancer Vaccine Conversation - Investing News Network
BriaCell Therapeutics Stock Faces Renewed Pressure as Biotech Volatility Tests Investor Conviction - kalkine.ca
BriaCell Therapeutics Corp. (TSX:BCT) Falls 4.24% as Clinical-Stage Risk and Volatility Pressure Sentiment - kalkine.ca
BriaCell Therapeutics Corp (BCTXW) Peer Comparison – Compare with Others - valueresearchonline.com
Briacell Therapeutics Corp (BCTX) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
BriaCell Therapeutics Stock Falls Sharply: Can TSX:BCT Stabilize After Renewed Biotech Selling Pressure? - kalkine.ca
BriaCell Therapeutics Corp. (TSX:BCT) Gains Momentum as Immunotherapy Pipeline Progress Supports Investor Optimism - kalkine.ca
BriaCell Therapeutics (TSX:BCT) Advances 6.6% on a Run of Pipeline Milestones - kalkine.ca
BriaCell in Focus: TSX: BCT Investors Watch Major Immunotherapy Milestones Ahead of Clinical Data - kalkine.ca
BriaCell Therapeutics Stock Slides 13.31%: Can Clinical Execution Overcome Renewed Biotech Pressure? - kalkine.ca
BriaCell stock choppy on melanoma vaccine milestone - Investing.com
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™ - Yahoo Finance
BriaCell’s saliva test could personalize an off-the-shelf melanoma vaccine - Stock Titan
BriaCell (BCTXZ) Session: Advances 2.54% to $0.10 in Latest Trading; Next Test: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingShort Term Trading Ideas - vinanet.vn
BriaCell (BCTXL) Stock: Trades in a Narrow Directional Range at $1.00 in Latest Trading; Chart Watch: the Price Remains Bounded by the Supplied Support and Resistance under the Current SnapshotFibonacci Fan - vinanet.vn
Why Did BriaCell Therapeutics (TSX:BCT) Surge 12.37% on 19 August 2026? - kalkine.ca
BriaCell (BCTX) Results Breakdown: Reported EPS Tops Expectations in the Current Update; After Earnings - vinanet.vn
BriaCell Therapeutics Stock Rises 3.19% as Phase 3 Breast Cancer Trial and Bria-IMT Progress Draw Investor Interest - kalkine.ca
BriaCell Therapeutics Stock: A Breast-Cancer Immunotherapy Nears Late-Stage Data - kalkine.ca
BCTX Q2 2026 Earnings: Narrower-Than-Expected Loss of -$2.58 Beats Estimates by 47.22%Revenue Recognition Risk - Vinanet
Briacell Therapeutics Corp (BCTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BCTXL Holds Steady at $0.85 as BriaCell Warrant Trades in Tight RangeVolume Nodes - Vinanet
BriaCell Therapeutics Corp (TSX:BCT) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Execution Concerns Pressure Sentiment - kalkine.ca
Enterprise value to EBIT forward of BriaCell Therapeutics Corp. – BOATS:BCTXL - TradingView
BriaCell Therapeutics Corp. (BCTXZ) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Briacell Therapeutics Corp (BCTX) Stock News Today - TradingKey
BCTX Q2 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline AdvancesRevenue Growth Outlook - vinanet.vn
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer - Investing News Network
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer - The Manila Times
FDA clearance lets BriaCell test personalized prostate immunotherapy - Stock Titan
BriaCell Therapeutics (BCTX) Rises 3.86% to $3.5 as Immuno-Oncology Interest BuildsVolatility Stop - vinanet.vn
Why Did BriaCell Therapeutics Corp. (TSX:BCT) Stock Fall 5.49% on 31 July 2026? - kalkine.ca
BriaCell Therapeutics2026 Funding Rounds & List of Investors - Tracxn
BriaCell Therapeutics Warrant (BCTXZ) Holds at $0.09 as Long-Dated Biotech Option Trades FlatUp Down Volume - dars.gov.et
BriaCell Therapeutics Corp Revenue Breakdown – TSX:BCT - TradingView
BriaCell Therapeutics Corp. Revenue Breakdown – BOATS:BCTXL - TradingView
Briacell Therapeutics Corp (BCTX) Institutional Confidence - TradingKey
Briacell Therapeutics Corp (BCTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BCTX|Briacell Therapeutics Corp|Price:3.338|Chg%:-0.022 - TradingKey
BCTXL Slips 7.87%: Support Test for BriaCell WarrantModified Schiff - vinanet.vn
Briacell Therapeutics Corp (BCTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Briacell Therapeutics Corp (BCTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Briacell Therapeutics Corp (BCTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BriaCell Therapeutics Market Sentiment - Benzinga España
Briacell Therapeutics Corp (BCTX) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):